In this issue:
OCARINA II: subcutaneous vs.intravenous ocrelizumab in MS
Relapse risk after IVF in women with MS
Cladribine & PRLs in MS
Pharmacologic therapies for fatigue in MS
CSF NfH as a biomarker of progression in secondary progressive MS
SPAM: secondary progressive MS despite early highly active treatment
Intermittent calorie restriction in MS
10-year disability trajectories in MS
Colour vision & long-term disease severity after a first demyelinating event
Mortality trends over time in Finnish MS patients
Please login below to download this issue (PDF)